Fisher & Paykel Healthcare (OTCMKTS:FSPKF) Lowered to Neutral at Citigroup

Citigroup downgraded shares of Fisher & Paykel Healthcare (OTCMKTS:FSPKFGet Rating) from a buy rating to a neutral rating in a report released on Monday, The Fly reports.

Several other equities research analysts have also recently issued reports on the stock. Morgan Stanley initiated coverage on shares of Fisher & Paykel Healthcare in a research report on Wednesday, November 16th. They set an overweight rating for the company. Royal Bank of Canada initiated coverage on shares of Fisher & Paykel Healthcare in a report on Wednesday, December 21st. They set an underperform rating for the company. Finally, The Goldman Sachs Group upgraded Fisher & Paykel Healthcare from a neutral rating to a conviction-buy rating in a report on Thursday, November 17th.

Fisher & Paykel Healthcare Stock Performance

Shares of OTCMKTS:FSPKF opened at $16.36 on Monday. Fisher & Paykel Healthcare has a 52-week low of $10.24 and a 52-week high of $20.78. The business has a fifty day moving average of $14.09 and a two-hundred day moving average of $12.89.

About Fisher & Paykel Healthcare

(Get Rating)

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital.

See Also

The Fly logo

Receive News & Ratings for Fisher & Paykel Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fisher & Paykel Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.